Results 101 to 110 of about 2,860,326 (352)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.

PLoS Pathogens, 2022
Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it is unknown if antibodies elicited by infection with these variants target the same or different regions of the viral spike as antibodies elicited by earlier viral ...
Allison J Greaney, Tyler N Starr, Rachel T Eguia, Andrea N Loes, Khadija Khan, Farina Karim, Sandile Cele, John E Bowen, Jennifer K Logue, Davide Corti, David Veesler, Helen Y Chu, Alex Sigal, Jesse D Bloom   +13 more
doaj   +1 more source

Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections [PDF]

, 2018
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide.
Borrás, Francesc E., del Portillo, Hernando A., Fraile Sauce, Lorenzo José, Montaner Tarbes, Sergio Roberto, Montoya, Maria, Novell, Elena, Tarancón, Vicens   +6 more
core   +4 more sources

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Science, 2020
An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat ...
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Z. Li, Shihua Li, Y. Bi, Yang Yang, Y. Gong, Haixia Xiao, Z. Fan, Shuguang Tan, Guizhen Wu, W. Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, J. Qi, G. Gao, F. Gao, Lei Liu   +24 more
semanticscholar   +1 more source

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

Kinetics of viral load and antibody response in relation to COVID-19 severity.

Journal of Clinical Investigation, 2020
The SARS-CoV-2 is the causative agent for COVID-19 pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID-19 patients.
Yanqun Wang, Lu Zhang, L. Sang, F. Ye, Shicong Ruan, Bei Zhong, T. Song, A. Alshukairi, Rongchang Chen, Zhaoyong Zhang, Mian Gan, Airu Zhu, Yongbo Huang, L. Luo, C. K. Mok, Manal M. Al Gethamy, H. Tan, Zhengtu Li, Xiaofang Huang, Fang Li, Jing Sun, Yanjun Zhang, Liyan Wen, Yuming Li, Zhaoming Chen, Z. Zhuang, Jianfen Zhuo, Chunke Chen, Lijun Kuang, Junxiang Wang, Huibin Lv, Yongliang Jiang, Min Li, Yimin Lin, Ying Deng, Lan-fong Tang, Jieling Liang, Jicheng Huang, S. Perlman, N. Zhong, Jingxian Zhao, J. S. Malik Peiris, Yimin Li, Jincun Zhao   +43 more
semanticscholar   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?

Viruses, 2012
The immune response against some viral pathogens, in particular those causing chronic infections, is often ineffective notwithstanding a robust humoral neutralizing response.
Roberto Burioni, Laura Solforosi, Massimo Clementi, Roberta A. Diotti, Matteo Castelli, Elena Criscuolo, Nicola Clementi, Giuseppe Sautto, Mancini Nicasio   +8 more
doaj   +1 more source

Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection

Human Vaccines & Immunotherapeutics, 2021
Antibodies can provide antiviral protection through neutralization and recruitment of innate effector functions through the Fc domain. While neutralization has long been appreciated for its role in antibody-mediated protection, a growing body of work ...
Bronwyn M. Gunn, Shuangyi Bai
doaj   +1 more source

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

New England Journal of Medicine, 2020
Covid-19 Antibodies after Mild Infection Among 34 volunteers who had recovered from mild Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein declined wi...
F. J. Ibarrondo, J. Fulcher, David Goodman-Meza, J. Elliott, C. Hofmann, M. Hausner, Kathie G Ferbas, Nicole H. Tobin, G. Aldrovandi, O. Yang   +9 more
semanticscholar   +1 more source